Home>Events>Gene therapy and Gene-modified Cell Therapy Seminar - Regulatory and Scientific Guidance and Advice

MilliporeSigma BioReliance® Services

Gene therapy and Gene-modified Cell Therapy Seminar

Regulatory and Scientific Guidance and Advice

Tuesday, November 13, 2018, 12:00 - 4:30 PM at The Boston Marriott Cambridge

MilliporeSigma Vibrant M

Don’t miss this half day seminar to learn more about the latest regulatory thinking and technology advances in this fast-paced field. Gene and gene modified cell therapies have the power to provide transformative and life changing results to patients. At MilliporeSigma, we are proud to be an integral part of the rapid development of this exciting therapy area and we would like to share more about the advances in assay development for this exciting therapy area and how we help with our regulatory and scientific expertise.

Reserve your seat today. Space is very limited. We look forward to seeing you in Boston.

Agenda

12:00 PMRegistration and buffet lunch
 
1:00 PMRegulatory guidance for gene therapy and gene modified cell therapy products
 Leyla Diaz, Ph.D.
 
2:00 PMNext Generation Sequencing (NGS) and beyond - the development of a broad range rapid molecular method for contamination detection
 Adam Inche, D.Phil.
 
2:30 PMBreak
 
3:00 PMApplication of new technologies for better and more rapid analysis of novel therapies
 Leyla Diaz, Ph.D.
 
4:00 PMQuestions and Discussion
 
4:30 PMNetworking Cocktail Reception
 
6:00 PMClose
 
Adam Inche

Adam Inche, D.Phil.

Marketing Manager, Strategy Development, BioReliance® Biosafety Testing Services

Adam is a Marketing Manager for strategy development, MilliporeSigma BioReliance® Services. He is responsible for leading the commercialization efforts for new rapid molecular testing methods. Adam was previously the lead scientist at Viragen and Lab901 where he was involved with transgenic applications using lentiviral vectors and in the development of an automated electrophoresis platform respectively. Adam received his doctorate in cancer cell biology from Oxford University in the United Kingdom.

Leyla Diaz

Leyla Diaz, Ph.D.

Principal Scientist, BioReliance® Biosafety Testing Services

Leyla is a Principal Scientist in Field Development Services, MilliporeSigma BioReliance® Services. She provides scientific and regulatory input in biosafety testing and characterization of biological therapeutic products. Leyla has twelve years of industry experience in product development of therapeutic antibodies and assay development for large molecules and vaccines. Leyla received her doctorate from the University of Maryland, College Park followed by a postdoctoral fellowship at the University of California, San Francisco.

Venue Information

Boston Marriott Cambridge
50 Broadway, Cambridge, MA 02142